Crinetics Pharmaceuticals (CRNX) Stock Overview
A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
CRNX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Crinetics Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$42.31 |
| 52 Week High | US$62.53 |
| 52 Week Low | US$24.10 |
| Beta | 0.33 |
| 1 Month Change | 24.08% |
| 3 Month Change | 36.00% |
| 1 Year Change | -28.19% |
| 3 Year Change | 149.76% |
| 5 Year Change | 189.79% |
| Change since IPO | 72.62% |
Recent News & Updates
Recent updates
Crinetics: FDA Approval And Expansion Of Palsonify In Focus, Maintaining 'Buy' Rating
Sep 26A Look At The Intrinsic Value Of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Jun 17
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Apr 23Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness
Jan 02We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely
Oct 02Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech
Aug 12Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation
Jun 01Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data
May 23Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)
Feb 29Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Nov 28Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?
Aug 08Shareholder Returns
| CRNX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -7.5% | -1.6% | -1.2% |
| 1Y | -28.2% | -7.0% | 15.1% |
Return vs Industry: CRNX underperformed the US Pharmaceuticals industry which returned -7% over the past year.
Return vs Market: CRNX underperformed the US Market which returned 15.1% over the past year.
Price Volatility
| CRNX volatility | |
|---|---|
| CRNX Average Weekly Movement | 10.2% |
| Pharmaceuticals Industry Average Movement | 9.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CRNX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CRNX's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 437 | R. Struthers | www.crinetics.com |
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing’s disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors.
Crinetics Pharmaceuticals, Inc. Fundamentals Summary
| CRNX fundamental statistics | |
|---|---|
| Market cap | US$4.16b |
| Earnings (TTM) | -US$369.83m |
| Revenue (TTM) | US$1.39m |
Is CRNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRNX income statement (TTM) | |
|---|---|
| Revenue | US$1.39m |
| Cost of Revenue | US$246.02m |
| Gross Profit | -US$244.63m |
| Other Expenses | US$125.21m |
| Earnings | -US$369.83m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 06, 2025
| Earnings per share (EPS) | -3.93 |
| Gross Margin | -17,573.71% |
| Net Profit Margin | -26,568.53% |
| Debt/Equity Ratio | 0% |
How did CRNX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/16 22:15 |
| End of Day Share Price | 2025/10/16 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Crinetics Pharmaceuticals, Inc. is covered by 21 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| David Lebowitz | Citigroup Inc |